Crossmark

Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples

Crossref DOI link: https://doi.org/10.1186/s40425-019-0807-6

Published Online: 2019-11-21

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Scott, Eleanor M.

Jacobus, Egon J.

Lyons, Brian

Frost, Sally

Freedman, Joshua D.

Dyer, Arthur

Khalique, Hena

Taverner, William K.

Carr, Alison

Champion, Brian R.

Fisher, Kerry D.

Seymour, Len W. https://orcid.org/0000-0003-3825-0841
Duffy, Margaret R.
Funding

Funding for this research was provided by:

Cancer Research UK (C5255/A20936, C552/A17720, C552/A17720, C552/A17720, C552/A17720, C552/A17720)

Kay Kendall Leukaemia Fund (KKL1050)

Engineering and Physical Sciences Research Council (EP/L024012/1, NA)

Medical Research Council (NA, NA, NA)
License Information

Text and Data Mining valid from 2019-11-21
More Information

Article History

Received: 12 June 2019

Accepted: 6 November 2019

First Online: 21 November 2019

Ethics approval and consent to participate

: Ascites samples were acquired with informed consent from routine drainage of cancer patients at the Churchill Hospital, Oxford, UK. Ethical approval for the study was gained from the institutional review board and research ethics committee of the Oxford Centre for Histopathology Research (Reference 09/H0606/5 + 5) in accordance with the UK Human Tissue Act 2004 and the Declaration of Helsinki.

: Not applicable.

: LWS, BRC and KDF own equity or share options in PsiOxus Therapeutics (Oxford, UK), which is leading clinical development of EnAd and its derivatives.